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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine whether nCPAP as the primary modality of treatment is effective and safe for treating respiratory distress in the term
neonate (≥ 37 weeks gestation).
We will explore potential sources of clinical heterogeneity through the following a priori subgroup analysis:
1. Age of infant at randomisation (< 6 hours, 6 to 12 hours, > 12 hours to 24 hours)
2. Setting (neonatal intensive care unit; non-tertiary special care nursery)
3. Level of continuing distending pressure used (≤ 5 cm H 0; ≥ 6 cm H 0)
4. Types of nCPAP (via continuous flow e.g. bubble nCPAP; variable flow nCPAP e.g. Infant Flow Driver)
5. Delivery system (nasal cannulae (short); nasal cannulae (long); nasal mask)
6. Method of oxygen delivery (ambient oxygen (crib, headbox); low-flow nasal cannulae; high-flow nasal cannulae)
7. Method of birth (caesarean section; vaginal delivery)
8. Reason for respiratory distress (e.g. hyaline membrane disease; transient tachypnoea of the newborn; bacterial pneumonia;
meconium aspiration syndrome; persistent pulmonary hypertension).
Sensitivity analysis
1Nasal continuous positive airway pressure (nCPAP) for term neonates with respiratory distress (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
B A C K G R O U N D
Description of the condition
The most common cause of respiratory distress in preterm infants
is transient surfactant deficiency leading to hyaline membrane dis-
ease (respiratory distress syndrome). This condition becomes less
common as infants approach term gestation while other causes of
respiratory distress become more common (Miall 2011). These
include transient tachypnoea of the newborn; bacterial pneumo-
nia; meconium aspiration; perinatal asphyxia leading to persistent
pulmonary hypertension of the newborn; and pneumothorax, ei-
ther spontaneous or secondary to one of the former conditions
(Edwards 2013). The increasing number of term infants delivered
by caesarean section is reported to have increased the incidence of
respiratory distress in term infants (Edwards 2013). Each of these
conditions has a different underlying aetiology but may initially
present with the same set of physical signs making differentiation
initially difficult. The range of possible respiratory support modal-
ities that neonates with respiratory distress might require include
ambient oxygen via a crib or headbox, low-flow nasal cannulae,
high-flow nasal cannulae, continuous positive airway pressure and
mechanical ventilation (Rodriguez 2003).
Description of the intervention
Continuous positive airway pressure (CPAP) refers to the appli-
cation of heated and humidified positive pressure to the airway of
a spontaneously breathing infant throughout the respiratory cycle
(DiBlasi 2009). CPAP is seen as an alternative to intubation and
mechanical ventilation of preterm infants. Mechanical ventilation
can contribute to pulmonary growth arrest and the development of
chronic lung disease, and CPAP has been shown to be less injurious
to the lungs of newborn infants (DiBlasi 2009). CPAP is proposed
as an effective and safe method of support for term neonates with
respiratory distress. It is increasingly being introduced into non-
tertiary special care nursery units worldwide (Buckmaster 2007;
Roberts 2011, Australia; Donoghue 1998, New Zealand; Jónsson
1992, Scandinavia), and for use with larger, and term neonates.
Similarly to its use in preterm infants, CPAP can be used for term
infants as an alternative to mechanical ventilation. CPAP can pro-
vide additional respiratory support for neonates born in non-ter-
tiary care centres to decrease the need for neonatal transfer to the
higher-level tertiary NICU. The emotional distress to parents is
substantial when a baby is transferred (Frischer 1992); and there
are significant costs associated with transfer of an infant to a tertiary
hospital (Buckmaster 2007). However, CPAP has been described
as resource-and time-intensive, and caution has been advised with
its use in units that are not well staffed or experienced in its use
in infants (DiBlasi 2009). CPAP has been associated with adverse
effects such as pneumothorax (Migliori 2003); and trauma of the
nares of term and preterm infants (Jatana 2010; Robertson 1996).
There have been a number of Cochrane reviews investigating the
effectiveness of CPAP for preterm infants. Davis 2003 evaluated
the use of nasal CPAP after extubation for preventing morbid-
ity and found nasal CPAP to be effective in preventing failure of
extubation in preterm infants following a period of endotracheal
intubation and intermittent positive pressure ventilation (IPPV).
Davis 2001 compared extubation from low-rate intermittent pos-
itive airway pressure versus extubation after a trial of endotracheal
CPAP and recommended that preterm infants no longer requiring
endotracheal intubation and IPPV should be directly extubated
without a trial of endotracheal CPAP. Ho 2002 examined the ef-
fect of continuous distending pressure (CDP, continuous positive
airway pressure or continuous negative pressure) for respiratory
distress in preterm infants and concluded that CDP reduces mor-
tality, or the need for assisted ventilation and reduces the need
for IPPV. Subramaniam 2005 explored prophylactic (early) nasal
CPAP for preventing morbidity and mortality in very preterm in-
fants but found insufficient information to evaluate its effective-
ness in reducing the use of IPPV.
The pressure sources of CPAP can be broadly grouped into variable
and continuous flow systems (Yagui 2011). Variable flow devices
such as the Infant Flow Driver generate CPAP pressure by varying
the inspiratory flow. For example, a flow adjusted to 8L/min results
in an approximate nCPAP level of 5 cm H 0 (DiBlasi 2009).
Continuous flow variable pressure systems such as ’bubble’ CPAP
vary the CPAP pressure by a mechanism other than inspiratory
flow variation (Yagui 2011). The level of bubble CPAP pressure is
determined by the distance the distal end of the expiratory limb of
the tubing is placed into a water filled chamber: for example, 5 cm
below surface = 5 cm H 0 (DiBlasi 2009) and as the gas exits the
tube, it creates bubbles. The inspiratory flow may also be adjusted
with bubble CPAP to maintain the required level of CPAP (Yagui
2011). Higher CPAP pressures may be needed in order to recruit
lungs with low compliance. CPAP pressures from 5 cm H 0 up
to 12 cm H 0 have been used in the neonatal population (DiBlasi
2009). CPAP can be used either as a primary modality of respi-
ratory support (with escalation of support if CPAP fails), or as
a ’step-down’ method from a higher level of respiratory support.
CPAP as the primary modality can be instituted prophyllactically
(e.g. immediately after birth) or after clinical manifestations have
occurred. The interest of this systematic review is CPAP that is
delivered nasally (nCPAP). The most commonly used devices for
nCPAP delivery are short or long nasal prongs, and nasal masks
(DiBlasi 2009). nCPAP is contraindicated in infants with upper
airway abnormalities (i.e. cleft palate, choanal atresia, tracheoe-
sophageal fistula), unrepaired diaphragmatic hernia, severe cardio-
vascular instability, recurrent apneic episodes, and in patients with
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severe ventilatory impairment (pH 7.25, and PaCO 60 mm Hg)
(American Association for Respiratory Care 2004).
How the intervention might work
CPAP works by delivering a constant positive pressure to the spon-
taneously breathing infant’s airway. CPAP is most commonly de-
livered to the nasal airway opening using bi-nasal short prongs or
a nasal mask, and pressure is generated using a variety of devices.
CPAP pressure is maintained in the lungs due to the anatomic
seal that forms between the infant’s tongue and the soft palate
(DiBlasi 2009). CPAP’s mechanism of action is complex and only
partially understood but is believed to decrease the work of breath-
ing by increasing oxygenation through the stabilisation and re-
cruitment of collapsed alveoli (Thompson 2006). The functional
residual capacity is increased resulting in an increased alveolar sur-
face area for gas exchange and a decrease in intrapulmonary shunt
and endogenous surfactant is conserved. The breathing pattern
regularises with stabilisation of the rib cage, reducing recession
and increasing efficiency of the diaphragm (Thompson 2006). It
had been proposed that pressure oscillations during bubble CPAP
improve gas exchange (Lee 1998); however, this postulation was
not supported in a more recent study (Morley 2005).
Why it is important to do this review
The use of nCPAP in the preterm population is now widely used
but its efficacy and safety for the term population has not been
determined (Roberts 2011). It is also important for the long-term
outcomes for preterm and term neonates who receive nCPAP out-
side tertiary care centres to be examined (Roberts 2011). We were
unable to identify any systematic reviews that have assessed the
efficacy and safety of nCPAP in the term infant population. Thus,
the interest of this review is to determine whether nCPAP is a safe
and effective treatment (including most effective pressure) in the
term neonate.
O B J E C T I V E S
To determine whether nCPAP as the primary modality of treat-
ment is effective and safe for treating respiratory distress in the
term neonate (≥ 37 weeks gestation).
We will explore potential sources of clinical heterogeneity through
the following a priori subgroup analysis:
1. Age of infant at randomisation (< 6 hours, 6 to 12 hours, >
12 hours to 24 hours)
2. Setting (neonatal intensive care unit; non-tertiary special
care nursery)
3. Level of continuing distending pressure used (≤ 5 cm
H 0; ≥ 6 cm H 0)
4. Types of nCPAP (via continuous flow e.g. bubble nCPAP;
variable flow nCPAP e.g. Infant Flow Driver)
5. Delivery system (nasal cannulae (short); nasal cannulae
(long); nasal mask)
6. Method of oxygen delivery (ambient oxygen (crib,
headbox); low-flow nasal cannulae; high-flow nasal cannulae)
7. Method of birth (caesarean section; vaginal delivery)
8. Reason for respiratory distress (e.g. hyaline membrane
disease; transient tachypnoea of the newborn; bacterial
pneumonia; meconium aspiration syndrome; persistent
pulmonary hypertension).
Sensitivity analysis
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and quasi-randomised trials assessing
nCPAP as a primary modality of respiratory support. Cluster trials
will be accepted. Cross-over trials will be excluded.
Types of participants
Newborn infants (≥ 37 weeks gestation) with respiratory distress
requiring oxygen therapy and up to 28 days postnatal age. Infants
must be randomised within 24 hours post birth. Infants with a
cleft palate, choanal atresia, or tracheoesophageal fistula will be
excluded from the review.
Types of interventions
Nasal continuous positive airway pressure (nCPAP) versus ambi-
ent oxygen (via crib, headbox);
Nasal continuous positive airway pressure (nCPAP) versus low-
flow nasal cannulae; and
Nasal continuous positive airway pressure (nCPAP) versus high-
flow nasal cannulae.
Studies comparing CPAP versus intubation and assisted mechan-
ical ventilation will not be included in this review.
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Types of outcome measures
Primary outcomes
Mortality prior to hospital discharge;
Mortality following hospital discharge (up to one year post dis-
charge)
Secondary outcomes
Need for increased level of respiratory support (e.g. escalation of
respiratory support from nCPAP, ambient oxygen, low-flow nasal
cannulae or high-flow nasal cannulae);
Incidence of pneumothorax (defined as presence of air between
the visceral and parietal pleura, and lung collapse, Lim 2011) di-
agnosed by X-ray during treatment with intervention;
Length of total hospitalisation (days-at all hospitals);
Duration receiving oxygen therapy (days);
Weight at discharge home (grams);
Neurodevelopmental disability (after at least 18 months postnatal
age) defined as neurological abnormality including cerebral palsy
on clinical examination, developmental delay more than 2 stan-
dard deviations (SDs) below population mean on a standardised
test of development, or blindness (visual acuity < 6/60), or deaf-
ness (any hearing impairment requiring amplification);
Duration of ventilation (for infants requiring escalation from nC-
PAP);
Duration of CPAP (for infants requiring escalation from oxygen);
Nasal trauma (as described by authors) during treatment with
nCPAP;
Parental stress - measured using a validated scale (e.g. Parental
Stressor Scale: NICU (PSS: NICU, Miles 1993) (during treatment
with intervention);
Nurses’ workload - measured using a validated scale (e.g. Profes-
sional Assessment of Optimal Nursing Care Intensity Level (PA-
ONCIL, Fagerstrom 2000); and
Any adverse effects not predetermined but reported by the authors
(during treatment with intervention).
Search methods for identification of studies
We will use the standard search strategy of The Cochrane Neonatal
Review Group (CNRG) as documented in The Cochrane Library.
See the CNRG search strategy.
Electronic searches
Two review authors will perform the electronic database searches
independently. The standard search strategy of CNRG as described
in The Cochrane Library will be used. Randomised controlled tri-
als will be identified from databases-the Cochrane Central Regis-
ter of Controlled Trials (Issue 4, 2013), PubMed (from 1966 to
current), EMBASE (from 1988 to current) and CINAHL (from
1982 to current)-using the following subject headings (MeSH) and
text words:[infant-newborn OR infan*, OR Neonat*, AND [con-
tinuous positive airway pressure OR continuous distending pres-
sure OR CPAP OR CDP]. We will search clinical trials registries
for ongoing or recently completed trials (www.clinicaltrials.gov,
www.controlled-trials.com and www.who.int/ictrp). We will at-
tempt to identify all relevant studies regardless of language or pub-
lication status (published, unpublished and in press).
Searching other resources
We will communicate with expert informants and search bibli-
ographies of reviews and trials for references to other trials. We will
search previous reviews including cross-references, abstracts, con-
ferences and symposia proceedings of the Perinatal Society of Aus-
tralia and New Zealand and Pediatric Academic Societies (Amer-
ican Pediatric Society/Society for Pediatric Research, and Euro-
pean Society for Paediatric Research) from 1990 to current. If we
identify any unpublished trial, we will contact the corresponding
investigator for information. We will consider unpublished stud-
ies or studies only reported as abstracts as eligible for review if
methods and data can be confirmed by the author. We will con-
tact the corresponding authors of identified RCTs for additional
information about their studies when further data are required.
Data collection and analysis
We will use Cochrane’s standard systematic review methods as
documented in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011); and CNRG.
Selection of studies
Review authors will independently assess for inclusion all the po-
tential studies identified as a result of the search strategy. We will
resolve any disagreement through discussion or, if required, we
will consult a Cochrane review arbiter.
Specifically, we will:
1. Merge search results using reference management software
and remove duplicate records of the same report;
2. Examine titles and abstracts to remove irrelevant reports;
3. Retrieve the full text of the potentially relevant reports;
4. Link together multiple reports of the same study;
5. Examine full text reports for compliance of studies with
eligibility criteria;
6. Correspond with investigators, when appropriate, to clarify
study eligibility;
7. At all stages, note reasons for inclusion and exclusion of
articles; and resolve disagreements through consensus, or refer
for arbitration to the editorial base of CNRG if needed;
8. Make final decisions on study inclusion and proceed to data
collection;
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9. Resolve all discrepancies through a consensus process.
Data extraction and management
We will design a form to extract data. For eligible studies, review
authors will extract the data using the agreed form. We will resolve
discrepancies through discussion or, if required, we will consult a
review arbiter. We will enter data using Review Manager 5 soft-
ware and check for accuracy (RevMan 2012). When information
regarding any of the above is unclear, we will attempt to contact
authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Review authors will independently assess risk of bias for each study
using the criteria outlined in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We will resolve any
disagreement by discussion or by involving a review arbiter.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups. We will
assess the method as:
• low risk (any truly random process, e.g. random number table;
computer random number generator);
• high risk (any non-random process, e.g. odd or even date of
birth; hospital or clinic record number); or
• unclear risk.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to
conceal the allocation sequence in sufficient detail and determine
whether intervention allocation could have been foreseen in ad-
vance of, or during, recruitment or changed after assignment.
We will assess the methods as:
• low risk (e.g. telephone or central randomisation; consecutively
numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque en-
velopes, alternation; date of birth); or
• unclear risk.
(3) Blinding (checking for possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will judge studies
to be at low risk of bias if they were blinded or if we judge that the
lack of blinding could not have affected the results. We will assess
blinding separately for different outcomes or class of outcomes.
We will assess the risk of bias methods as:
low risk, high risk or unclear risk for participants;
low risk, high risk or unclear risk for personnel; or
low risk, high risk or unclear risk for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We will describe for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information is reported, or can be supplied by
the trial authors, we will re-include missing data in the analyses
which we undertake. We will assess the risk of bias methods as:
low risk (less than 20% missing data); high risk; or unclear risk.
(5) Selective reporting bias
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk (where it is clear that all of the study’s prespecified
outcomes and all expected outcomes of interest to the review have
been reported);
• high risk (where not all the study’s pre-specified outcomes have
been reported; one or more reported primary outcomes were not
pre-specified; outcomes of interest are reported incompletely and
so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported);
• unclear risk.
(6) Other sources of bias
We will describe for each included study any important concerns
we have about other possible sources of bias (e.g. early termination
of trial due to data-dependant process, extreme baseline imbalance,
etc.). We will assess whether each study was free of other problems
that could put it at risk of bias. We will assess other sources of bias
as: low risk; high risk; or unclear risk.
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to the above, we will assess the likely magnitude and
direction of the bias and whether we consider it likely to impact
on the findings. We will explore the impact of the level of bias
through undertaking sensitivity analyses (see Sensitivity analysis).
We will try to obtain the study protocols of all included studies.
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Each criterion will be judged as being at ’low risk’ of bias, ’high
risk’ of bias, or ’unclear risk’ of bias (for either lack of information
or uncertainty over the potential for bias).
Quality of evidence
We will assess the quality of evidence for the main comparison at
the outcome level using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach (Guyatt
2011a). This methodological approach considers evidence from
randomised controlled trials as high quality that may be down-
graded based on consideration of any of five areas: design (risk of
bias), consistency across studies, directness of the evidence, preci-
sion of estimates, and presence of publication bias (Guyatt 2011a).
The GRADE approach results in an assessment of the quality of
a body of evidence in one of four grades: 1) High: we are very
confident that the true effect lies close to that of the estimate of
the effect; 2) Moderate: we are moderately confident in the effect
estimate-the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different; 3)
Low: our confidence in the effect estimate is limited-the true effect
may be substantially different from the estimate of the effect; 4)
Very Low: we have very little confidence in the effect estimate-the
true effect is likely to be substantially different from the estimate
of effect (Schünemann 2013).
The review authors will independently assess the quality of the
evidence found for the following outcomes identified as critical or
important for clinical decision making: mortality prior to hospital
discharge; mortality following hospital discharge (up to one year
post discharge); need for increased level of respiratory support (e.g.
escalation of respiratory support from nCPAP, ambient oxygen,
low-flow nasal cannulae or high-flow nasal cannulae); incidence of
pneumothorax; length of total hospitalisation; duration receiving
oxygen therapy; neurodevelopmental disability.
In cases where we consider the risk of bias arising from inade-
quacies regarding concealment of allocation, randomised assign-
ment, complete follow-up or blinded outcome assessment to re-
duce our confidence in the effect estimates, we will downgrade
the quality of evidence accordingly (Guyatt 2011b). Consistency
will be evaluated by similarity of point estimates, extent of overlap
of confidence intervals and statistical criteria including measure-
ment of heterogeneity (I²). The quality of evidence will be down-
graded when inconsistency across study results is large and un-
explained (i.e. some studies suggest important benefit and others
no effect or harm without a clinical explanation; Guyatt 2011d).
Precision will be assessed accordingly with the 95% confidence in-
terval around the pooled estimation (Guyatt 2011c). When trials
were conducted in populations other than the target population,
we will downgrade the quality of evidence because of indirectness
(Guyatt 2011e).
Data (i.e. pooled estimates of the effects and corresponding 95%
confidence Interval) and explicit judgements for each of the above
aspects assessed will be entered into the Guideline Development
Tool, the software used to create ’Summary of findings’ tables (
GRADEpro 2008). All judgements involving the assessment of the
study characteristics described above will be explained in footnotes
or comments in the ’Summary of findings’ table.
Measures of treatment effect
The results of the studies will be analysed using the statistical pack-
age Review Manager 5 (RevMan 2012). Data will be summarised
in a meta-analysis if they are sufficiently homogeneous, both clin-
ically and statistically.
Dichotomous data
We will present results as risk ratios (RR) and risk differences (RD)
with 95% confidence intervals (CI) for dichotomous data. We will
calculate the number needed to treat for an additional beneficial
outcome (NNTB), or number needed to treat for an additional
harmful outcome (NNTH), and associated 95% CIs if there is a
statistically significant reduction (or increase) in RD.
Continuous data
For continuous data, we will use the mean difference (MD) if
outcomes are measured in the same way between trials.
Unit of analysis issues
The unit of analysis is the participating infant in individually ran-
domised trials and the neonatal unit (or sub-unit) for cluster ran-
domised trials. Cross-over trials will be excluded.
Cluster randomised trials:
We will include cluster randomised trials in the analyses along
with individually randomised trials. We will analyse them using
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions using an estimate of the intracluster cor-
relation coefficient (ICC) derived from the trial (if possible) or
from another source (Higgins 2011). If ICCs from other sources
are used, we will report this and conduct sensitivity analyses to
investigate the effect of variation in the ICC. If we identify both
cluster randomised trials and individually randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely. We will also acknowledge heterogeneity
in the randomisation unit and perform a separate meta-analysis.
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Dealing with missing data
For all included studies, we will note levels of attrition. If data
from the trial reports are insufficient, unclear or missing, we will
attempt to contact the trial authors for additional information.
We will explore the impact of including studies with high levels of
missing data in the overall assessment of treatment effect by using
sensitivity analysis. For all outcomes we will carry out analyses, as
far as possible, on an intention-to-treat (ITT) basis, i.e. we will
attempt to include all participants randomised to each group in
the analyses and we will analyse all participants in the group to
which they were allocated, regardless of whether they received the
allocated intervention. The denominator for each outcome in each
trial will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
Statistical heterogeneity will be assessed by visual inspection of
forest plots, the I² statistic, and Chi² test. We will use the follow-
ing cut-offs as recommended by the CNRG for the reporting of
heterogeneity: less than 25%, no heterogeneity; 25% to 49%, low
heterogeneity; 50% to 74%, moderate heterogeneity; and 75% or
higher, high heterogeneity. In cases of moderate or high hetero-
geneity, we will explore the possible causes in terms of the pop-
ulation, intervention, comparison and outcome assessment, and
determine whether a meta-analysis is appropriate.
Assessment of reporting biases
We will try to obtain the study protocols of all included studies
and we will compare outcomes reported in the protocol to those
reported in the findings for each of the included studies. We will
investigate reporting and publication bias by examining the de-
gree of asymmetry of a funnel plot if there are at least 10 studies
reporting on the same outcome and included in the meta-analysis.
Where we suspect reporting bias (see ’(5) Selective reporting bias’
in Assessment of risk of bias in included studies above), we will
attempt to contact study authors asking them to provide missing
outcome data. Where this is not possible and the missing data
are thought to introduce serious bias, we will explore the impact
of including such studies in the overall assessment of results by a
sensitivity analysis.
Data synthesis
We will use the fixed-effect model in Review Manager 5 (RevMan
2012) for meta-analyses. For dichotomous data we will use typical
RR, RD, and NNTB or NNTH if there is a statistically significant
reduction (or increase) in RD; and for continuous data we will use
typical MD or standard MD as measures of treatment effect. We
will use the generic inverse variance strategy to combine cluster
trials.
Subgroup analysis and investigation of heterogeneity
1. Age of infant at randomisation (< 6 hours, 6 to 12 hours, >
12 hours to 24 hours)
2. Setting (neonatal intensive care unit; non-tertiary special
care nursery)
3. Level of continuing distending pressure used (≤ 5 cm
H 0; ≥ 6 cm H 0)
4. Types of CPAP (via continuous flow e.g. bubble nCPAP;
variable flow nCPAP e.g. Infant Flow Driver)
5. Delivery system (nasal cannulae (short), nasal cannulae
(long), nasal mask)
6. Method of oxygen delivery (ambient oxygen (crib,
headbox), low-flow nasal cannulae, high-flow nasal cannulae)
7. Method of birth (caesarean section vs. vaginal delivery)
8. Reason for respiratory distress (e.g. hyaline membrane
disease; transient tachypnoea of the newborn; bacterial
pneumonia; meconium aspiration syndrome; persistent
pulmonary hypertension).
Sensitivity analysis
We will explore methodological heterogeneity through the use of
sensitivity analysis. We will assess studies at low risk of bias as those
with adequate sequence generation, allocation concealment, and
less than 10% losses with ITT analysis.
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